Zobrazeno 1 - 10
of 3 478
pro vyhledávání: ''
Autor:
Tapan M. Kadia, Patrick K. Reville, Xuemei Wang, Caitlin R. Rausch, Gautam Borthakur, Naveen Pemmaraju, Naval G. Daver, Courtney D. DiNardo, Koji Sasaki, Ghayas C. Issa, Maro Ohanian, Guillermo Montalban-Bravo, Nicholas J. Short, Nitin Jain, Alessandra Ferrajoli, Kapil N. Bhalla, Elias Jabbour, Koichi Takahashi, Rashmi Malla, Kelly Quagliato, Rashmi Kanagal-Shamanna, Uday R. Popat, Michael Andreeff, Guillermo Garcia-Manero, Marina Y. Konopleva, Farhad Ravandi, Hagop M. Kantarjian
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(33)
PURPOSE The combination of venetoclax and 5-azacitidine (5-AZA) for older or unfit patients with acute myeloid leukemia (AML) improves remission rates and survival compared with 5-AZA alone. We hypothesized that the addition of venetoclax to cladribi
Autor:
David M. O'Malley, Maryna Neffa, Bradley J. Monk, Tamar Melkadze, Marilyn Huang, Anna Kryzhanivska, Iurie Bulat, Tarek M. Meniawy, Andrea Bagameri, Edward W. Wang, Bernard Doger de Speville Uribe, Roberto Hegg, Waldo Ortuzar Feliu, Marek Ancukiewicz, Iwona Lugowska
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(7)
PURPOSE Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte–associated antigen-4) are two new checkpoint inhibitors emerging as promising investigational agents for the treatment of advanced cervical cancer. This phase
Autor:
Ian E. Krop, Seock-Ah Im, Carlos Barrios, Hervé Bonnefoi, Julie Gralow, Masakazu Toi, Paul A. Ellis, Luca Gianni, Sandra M. Swain, Young-Hyuck Im, Michelino De Laurentiis, Zbigniew Nowecki, Chiun-Sheng Huang, Louis Fehrenbacher, Yoshinori Ito, Jigna Shah, Thomas Boulet, Haiying Liu, Harrison Macharia, Peter Trask, Chunyan Song, Eric P. Winer, Nadia Harbeck
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(5)
PURPOSE We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)–positive early breast cancer (EBC) treatment by replacing taxanes and trastuzumab with trastuzumab emtansine (T-DM1). METHODS The
Autor:
Masayuki Takeda, Tomohide Tamura, Kohei Akiyoshi, Masahiro Morise, Naofumi Shinagawa, Toshiaki Saeki, Naoki Inui, Morihito Okada, Shunichi Sugawara, Kaoru Kubota, Yasutaka Watanabe, Akito Hata, Isamu Okamoto
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(2)
PURPOSE We evaluated the efficacy and safety of fosnetupitant (FosNTP) versus fosaprepitant (FosAPR) for preventing highly emetogenic chemotherapy-induced nausea and vomiting. This phase III study was the first head-to-head comparison between two dif
Autor:
Christopher J. Patterson, Lian Xu, Tanya Siddiqi, Maria Luisa Guerrera, Shayna Sarosiek, Zachary R. Hunter, Andrew R. Branagan, Xia Liu, Carly Leventoff, Catherine A Flynn, Ranjana H. Advani, Kirsten Meid, Nicholas Tsakmaklis, Maria Demos, Matthew S. Davids, Guang Yang, Amanda Kofides, Timothy P White, Manit Munshi, Steven P. Treon, Jorge J. Castillo, Richard R. Furman, John N. Allan
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(1)
PURPOSE BCL2 is overexpressed and confers prosurvival signaling in malignant lymphoplasmacytic cells in Waldenström macroglobulinemia (WM). Venetoclax is a potent BCL2 antagonist and triggers in vitro apoptosis of WM cells. The activity of venetocla
Autor:
David Nunns, Hein Putter, Derek Cruickshank, V Asher, Jayanthi S. Lea, Charles F Levenback, Timothy J. Duncan, Paul DiSilvestro, Jiri Bouda, Ming Y. Tjiong, Mario M. Leitao, Ingo B. Runnebaum, Martin Widschwendter, Geertruida H. de Bock, Kalyan Dhar, Joanne A. de Hullu, Pernille Tine Jensen, David Cibula, Nicola M. Spirtos, Preben Kjølhede, Willemien J. van Driel, Brigitte F. M. Slangen, Diane Provencher, Helena C. van Doorn, Ralph H Hermans, Christer Borgfeldt, Ate G J van der Zee, Eleonora B.L. van Dorst, Katja N. Gaarenstroom, Bradley J. Monk, Brynhildur Eyjolfsdottir, Ranjit Manchanda, Robert S. Mannel, Katharina Kieser, Aarti Sharma, Brian Slomovitz, Krishnansu S. Tewari, Jo Bailey, Linda Van Le, Maaike H. M. Oonk, David Nugent, David M. O'Malley, Karl Tamussino, Jacobus van der Velden, Patricia Ellis, Al Covens, Connie Palle, Stephen Attard-Montalto, David Luesley, Melissa A. Geller, Cathrine M Holland, Margareta Lood, Par Persson, D. Boll, Mats Brännström, Daniel H Tobias, Ignace Vergote, Peter Baldwin, Carien L. Creutzberg
Publikováno v:
Oonk, M H M, Slomovitz, B, Baldwin, P J W, van Doorn, H C, van der Velden, J, de Hullu, J A, Gaarenstroom, K N, Slangen, B F M, Vergote, I, Brännström, M, van Dorst, E B L, van Driel, W J, Hermans, R H, Nunns, D, Widschwendter, M, Nugent, D, Holland, C M, Sharma, A, DiSilvestro, P A, Mannel, R, Boll, D, Cibula, D, Covens, A, Provencher, D, Runnebaum, I B, Luesley, D, Ellis, P, Duncan, T J, Tjiong, M Y, Cruickshank, D J, Kjølhede, P, Levenback, C F, Bouda, J, Kieser, K E, Palle, C, Spirtos, N M, O'Malley, D M, Leitao, M M, Geller, M A, Dhar, K, Asher, V, Tamussino, K, Tobias, D H, Borgfeldt, C, Lea, J S, Bailey, J, Lood, M, Eyjolfsdottir, B, Attard-Montalto, S, Tewari, K S, Manchanda, R, Jensen, P T, Persson, P, Van Le, L, Putter, H, de Bock, G H, Monk, B J, Creutzberg, C L & van der Zee, A G J 2021, ' Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node : Results of GROINSS-V II ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 32, pp. 3623-3632 . https://doi.org/10.1200/JCO.21.00006
Journal of Clinical Oncology, 39(32), 3623-+. LIPPINCOTT WILLIAMS & WILKINS
Journal of Clinical Oncology, 39(32), 3623-3632. American Society of Clinical Oncology
Journal of Clinical Oncology, 39, 32, pp. 3623-3632
Journal of Clinical Oncology, 39, 3623-3632
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(32), 3623-3632. AMER SOC CLINICAL ONCOLOGY
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(32), 3623-3632. American Society of Clinical Oncology
Journal of clinical oncology, 39(32), 3623-3632. American Society of Clinical Oncology
Journal of Clinical Oncology, 39(32), 3623-+. LIPPINCOTT WILLIAMS & WILKINS
Journal of Clinical Oncology, 39(32), 3623-3632. American Society of Clinical Oncology
Journal of Clinical Oncology, 39, 32, pp. 3623-3632
Journal of Clinical Oncology, 39, 3623-3632
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(32), 3623-3632. AMER SOC CLINICAL ONCOLOGY
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(32), 3623-3632. American Society of Clinical Oncology
Journal of clinical oncology, 39(32), 3623-3632. American Society of Clinical Oncology
PURPOSE The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sen
Autor:
Bradley R. Pieters, Fernanda G. Herrera, Antoine Engelen, Philippe Maingon, Santhanam Sundar, Christopher D Scrase, John Armstrong, Alphonsus C. M. van den Bergh, Ana Boladeras, Elzbieta van der Steen-Banasik, Michel Bolla, Amit Bahl, Laurence Collette, Christian Carrie, Joe M O'Sullivan, Demetrios Andreopoulos, Jihane Boustani, Annerie Slot, Anouk Neven, Jan Jansa, David Azria, Karine Peignaux-Casasnovas
Publikováno v:
Journal of clinical oncology, vol. 39, no. 27, pp. 3022-3033
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(27), 3022-3033. AMER SOC CLINICAL ONCOLOGY
Journal of clinical oncology, 39(27), 3022-3033. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(27), 3022-3033. AMER SOC CLINICAL ONCOLOGY
Journal of clinical oncology, 39(27), 3022-3033. American Society of Clinical Oncology
PURPOSE The European Organisation for Research and Treatment of Cancer (EORTC) trial 22991 ( NCT00021450 ) showed that 6 months of concomitant and adjuvant androgen suppression (AS) improves event- (EFS, Phoenix) and clinical disease-free survival (D
Autor:
Haiyan Zhang, Zhiping Fan, Fen Huang, Lijie Han, Yajing Xu, Na Xu, Lan Deng, Shunqing Wang, Dongjun Lin, Xiaodan Luo, Qing Zhang, Xiaodan Liu, Xudong Li, Xinquan Liang, Shuangfeng Xie, Hong Qu, Sijian Yu, Hongsheng Zhou, Pengcheng Shi, Li Xuan, Ren Lin, Hui Liu, Hua Jin, Jing Sun, Qifa Liu
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 41(2)
PURPOSE It remains controversial whether busulfan-based versus total body irradiation (TBI)–based regimens have comparable outcomes in patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem-cell transplantation (a
Autor:
Arya Amini, Lucinda Morris, Ethan B. Ludmir, Benjamin Movsas, Reshma Jagsi, Noam A. VanderWalde
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(16)
Radiation therapy (RT) is a commonly used modality in the treatment of older adults with cancer, and RT represents an attractive oncologic treatment option, providing a noninvasive local therapy with limited systemic side effects. The Journal of Clin
Autor:
Marc-Oliver Grimm, Bernd Jürgen Schmitz-Dräger, Uwe Zimmermann, Christine Barbara Grün, Gustavo Bruno Baretton, Marc Schmitz, Susan Foller, Katharina Leucht, Martin Schostak, Friedemann Zengerling, Ulrike Schumacher, Wolfgang Loidl, Johannes Meran
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(19)
PURPOSE Several anti–programmed cell death (ligand)-1 (PD-[L]1) immune checkpoint inhibitors are approved in advanced/metastatic urothelial carcinoma (mUC). Recently, improved activity of an anti–PD-1/anticytotoxic T-cell lymphocyte-4 (CTLA-4) co